Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia. or B, with and without Inhibitors: An Integrated Analysis of Safety

被引：0

作者：

Acharya, Suchitra ^{[1
]}

Matino, Davide ^{[2
]}

Mahlangu, Johnny ^{[3
,4
]}

Turich, Carrie ^{[5
]}

Hwang, Eunhee ^{[6
]}

Hinnershitz, Tina ^{[7
]}

Mefyod, Eugeny ^{[8
]}

Palladino, Andrew ^{[6
]}

Biondo, Francesca ^{[7
]}

Gould, Travis ^{[5
]}

Teeter, John ^{[7
]}

机构：

[1] Cohen Childrens Med Ctr New York, New Hyde Pk, NY USA

[2] Thrombosis & Atherosclerosis Res Inst TaARI, Hamilton, ON, Canada

[3] Univ Witwatersrand, Johannesburg, South Africa

[4] Natl Hlth Lab Serv, Johannesburg, South Africa

[5] Pfizer Inc, New York, NY USA

[6] Pfizer Inc, Collegeville, PA USA

[7] Pfizer Inc, Groton, CT USA

[8] Pfizer Inc, Smolensk, Russia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174682

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 45 条

[21] Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation
Adams, M
Breckler, L
Stevens, P
Thom, J
Baker, R
Oostryck, R
HAEMATOLOGICA, 2004, 89 (08) : 985 - 990
[22] Patients with hemophilia A and B have increased platelet tissue factor pathway inhibitor (TFPI)
Ellery, P.
Maroney, S.
Hilden, I.
Sorensen, B.
Gill, J.
Mast, A.
HAEMOPHILIA, 2012, 18 : 41 - 41
[23] Difference in tissue factor pathway inhibitor (TFPI) levels between hemophilia A and B patients
Tardy-Poncet, B.
Piot, M.
Chapelle, C.
Berger, C.
Campos, L.
Mismetti, P.
Decousus, H.
Tardy, B.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 922 - 922
[24] Tissue Factor Pathway Inhibitor Causes Unresponsiveness to Activated Prothrombin Complex Concentrates for Hemophilia A Patients with Inhibitors
Ogiwara, Kenichi
Nogami, Keiji
Tanaka, Ichiro
Nishiya, Katsumi
Tsujii, Nobuyuki
Shima, Midori
BLOOD, 2010, 116 (21) : 1504 - 1504
[25] Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B
Gu, Ian-Ming
Patel, Chandra
Kauser, Katalin
HAEMOPHILIA, 2016, 22 : 49 - 49
[26] Plasma Tissue Factor Pathway Inhibitor (TFPI) Levels in Healthy Subjects and Patients with Hemophilia A and B
Gu, Jian-Ming
Patel, Chandra
Kauser, Katalin
BLOOD, 2015, 126 (23)
[27] A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers
Cardinal, M.
Kantaridis, C.
Zhu, T.
Sun, P.
Pittman, D. D.
Murphy, J. E.
Arkin, S.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (09) : 1722 - 1731
[28] DISSEMINATED INTRAVASCULAR COAGULATION IN RABBITS INDUCED BY ADMINISTRATION OF ENDOTOXIN OR TISSUE FACTOR - EFFECT OF ANTI-TISSUE FACTOR ANTIBODIES AND MEASUREMENT OF PLASMA EXTRINSIC PATHWAY INHIBITOR ACTIVITY
WARR, TA
RAO, LVM
RAPAPORT, SI
BLOOD, 1990, 75 (07) : 1481 - 1489
[29] The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls
Hellum, Marit
Franco-Lie, Isabel
Ovstebo, Reidun
Hauge, Truls
Henriksson, Carola E.
PLOS ONE, 2017, 12 (09):
[30] Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086
Parng, Chuenlei
Singh, Pratap
Pittman, Debra D.
Wright, Katherine
Leary, Beth
Patel-Hett, Sunita
Rakhe, Swapnil
Stejskal, James
Peraza, Marjorie
Dufield, Dawn
Murphy, John E.
Webster, Rob
JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (07) : 1995 - 2004

← 1 2 3 4 5 →